PHP
INBX icon

Parkman Healthcare Partners’s Inhibrx INBX Stock Holding History

Parkman Healthcare Partners’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3M Buy
+256,950
New +$25.7M 2.49% 10

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parkman Healthcare Partners's INBX Position: Q2 2026 in Review

Parkman Healthcare Partners opened a new position in Inhibrx (INBX) in Q2 2026: 256,950 shares worth $24.3M. The stake represents 2.49% of the portfolio and ranks #10 among its holdings.

163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Parkman Healthcare Partners held 256,950 shares of Inhibrx worth $24.3M as of Q2 2026.
  • Inhibrx was a new Parkman Healthcare Partners position in Q2 2026.
  • Inhibrx made up 2.49% of Parkman Healthcare Partners's portfolio in Q2 2026, its #10 holding.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.